US Edition
First drug to slow down progress of type 1 diabetes gets approval
- Teplizumab is the first drug approved in the UK to slow the progress of type 1 diabetes, allowing patients to live normal lives without insulin injections, according to the Medicines and Healthcare Regulatory Agency .
- The MHRA's approval is seen as a breakthrough, marking a turning point in type 1 diabetes treatment.
- Approximately 400,000 people in the UK live with type 1 diabetes, a condition where the immune system attacks insulin-producing cells in the pancreas.
- Teplizumab delays the onset of stage three type 1 diabetes by an average of three years in those aged eight and over.
9 Articles
9 Articles
The Independent
The Independent (US)Breakthrough drug that slows onset of type 1 diabetes set for UK release
Teplizumab can allow patients to live “normal lives” without the need for insulin injections
Drug that slows onset of type 1 diabetes licensed for use in UK-first
The cost-effectiveness of the drug for NHS roll-out will now be assessed by the National Institute for Health and Care Excellence. A groundbreaking drug that slows down the development of type 1 diabetes has been licensed for use in the UK. Teplizumab can allow patients to live “normal lives” without the need for insulin injections. Experts hailed the decision by the Medicines and Healthcare Regulatory Agency (MHRA) as a “breakthrough moment” th…
MHRA Approves First T1D Immunotherapy in UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (Tzield, Aventis Pharma Limited) as the UK’s first immunotherapy for type 1 diabetes (T1D). The drug is licensed for adults and children aged 8 years and older with stage 2 T1D to delay progression to stage 3. Teplizumab was approved in the US in […] The post MHRA Approves First T1D Immunotherapy in UK first appeared on News Health.
Teplizumab authorised by the MHRA – UK Diabetes Inpatient Forum
The first ever immunotherapy for type 1 diabetes has now been licensed for use in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed teplizumab, also known as Tzield, is safe and effective at delaying the development of type 1 diabetes for people in the early stages of the condition. Sanofi has received authorisation for teplizumab – the world’s first licensed immunotherapy for type 1 diabetes, tackling the root…
Coverage Details
Bias Distribution
- 60% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
